Has Jose Grijalva, MD received payments from drug or device companies?

Yes. Drug and device makers reported $20,773 in general payments to Jose Grijalva, MD across 59 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jose Grijalva, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jose Grijalva, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jose Grijalva, MD

Psychiatry · Austin, TXNPI 1932690419

Payments from drug & device makers

$20,773in general payments, 2019–2025

Across 59 payments — averaging $352.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Acadia Pharmaceuticals Inc$19K
Neurocrine Biosciences, Inc.$541
Teva Pharmaceuticals USA, Inc.$428
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$168
Otsuka America Pharmaceutical, Inc.$158
AbbVie$125
plus $26 from 1 others

What the payments were for

Speaking & faculty fees$15,10073%
Travel & lodging$2,26111%
Food & beverage$3,22116%
Education$1911%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Acadia Pharmaceuticals Inc	39	$19,327
Neurocrine Biosciences, Inc.	9	$541
Teva Pharmaceuticals USA, Inc.	4	$428
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$168
Otsuka America Pharmaceutical, Inc.	3	$158
AbbVie	1	$125
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

NUPLAZID$18,561
INGREZZA$359
VRAYLAR$125
REXULTI$123
Austedo XR$122

How this compares

$20,773 in reported general payments places this provider in the 90th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas →

Medicare billing

Part B allowed, 2024

$123,616

Medicare patients

447

Services billed

1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
BelsomraSuvorexant	14	$4,734
Paliperidone ErPaliperidone	18	$3,189
RivastigmineRivastigmine Tartrate	12	$1,005
Clonazepam	26	$671
Lorazepam	33	$546
Quetiapine Fumarate	21	$275
Sertraline Hcl	14	$250
Buspirone Hcl	19	$203
Trazodone Hcl	27	$105
Bupropion XlBupropion Hcl	12	$79

Paid to pharmacies, not to this prescriber.

Other psychiatry in Austin

David BrownAustin$15.8M
Divyansu PatelAustin$2.8M
Donald GarciaAustin$2.8M
Arvinder Pal WaliaAustin$2.5M
Charles SweetAustin$520K
Charles NemeroffAustin$429K
Scott BartleyDallas$42.7M
Rajinder ShiwachDesoto$15.4M
Darin OkudaDallas$14.7M
Jason MensahBeaumont$10.3M

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →